- Home
- EWTX vs LGND Comparison
EWTX vs LGND Comparison
Compare EWTX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- LGND
- Stock Information
- Founded
- EWTX 2017
- LGND 1987
- Country
- EWTX United States
- LGND United States
- Employees
- EWTX N/A
- LGND N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- EWTX Health Care
- LGND Health Care
- Exchange
- EWTX Nasdaq
- LGND Nasdaq
- Market Cap
- EWTX 2.6B
- LGND 2.3B
- IPO Year
- EWTX 2021
- LGND 1992
- Fundamental
- Price
- EWTX $27.39
- LGND $117.36
- Analyst Decision
- EWTX Buy
- LGND Strong Buy
- Analyst Count
- EWTX 6
- LGND 6
- Target Price
- EWTX $44.83
- LGND $145.00
- AVG Volume (30 Days)
- EWTX 818.6K
- LGND 119.5K
- Earning Date
- EWTX 02-20-2025
- LGND 02-25-2025
- Dividend Yield
- EWTX N/A
- LGND N/A
- EPS Growth
- EWTX N/A
- LGND 160.46
- EPS
- EWTX N/A
- LGND 2.47
- Revenue
- EWTX N/A
- LGND $152,422,000.00
- Revenue This Year
- EWTX N/A
- LGND $26.86
- Revenue Next Year
- EWTX N/A
- LGND $14.95
- P/E Ratio
- EWTX N/A
- LGND $45.27
- Revenue Growth
- EWTX N/A
- LGND N/A
- 52 Week Low
- EWTX $14.90
- LGND $67.72
- 52 Week High
- EWTX $38.12
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- EWTX 47.43
- LGND 58.49
- Support Level
- EWTX $23.08
- LGND $102.79
- Resistance Level
- EWTX $30.30
- LGND $112.61
- Average True Range (ATR)
- EWTX 1.70
- LGND 4.02
- MACD
- EWTX 0.19
- LGND 0.87
- Stochastic Oscillator
- EWTX 59.70
- LGND 98.85
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.